Latest News

(UroToday.com) Nadofaragene firadenovec is a non-replicating recombinant type-5 adenovirus vector-based gene therapy that delivers a copy of the human IFNα2b gene. Adenoviruses provide short-term, high but transient expression of the gene of interest in a relatively broad range of host cells. The Phase III trial of nadofaragene firadenovec for Bacillus Calmette Guerin (BCG) unresponsive on muscle […]

(UroToday.com) Most patients with newly diagnosed bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with Bacillus Calmette Guerin (BCG) is recommended by many guideline bodies due to proven benefits in disease recurrence. For patients who become BCG-unresponsive, there have been very limited […]

(UroToday.com) The goals of treatment of non muscle invasive bladder cancer (NMIBC) are to reduce recurrence and prevent progression, however, despite optimal treatment, ≥50% of patients who demonstrated an initial response to Bacillus Calmette Guerin (BCG) will experience recurrence and progression and become BCG-unresponsive. With limited treatment options, there is an unmet medical need for local, effective, […]

Single nucleotide polymorphism-based genetic risk score (GRS) has been developed and validated for prostate cancer (PCa) risk assessment. As GRS is population standardized, its value can be interpreted as a relative risk to the general population.

We aimed to evaluate the correlation between PSMA uptake and magnetic resonance imaging (MRI) PI-RADS of simultaneous [68Ga]Ga-PSMA-11 PET/MRI regarding PI-RADS version 2.0 and 2.1 respectively and compared the difference between these two versions.

To explore the practice and views of uro-oncologists in the UK regarding their use of chemotherapy and androgen receptor-targeted agents (ARTAs) in patients with newly-diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

To compare the prognostic capabilities and clinical utility of the cell cycle progression (CCP) gene expression classifier test, multiparametric magnetic resonance imaging (mpMRI) with Prostate Imaging Reporting and Data System (PI-RADS) scoring, and clinicopathologic data in select prostate cancer (PCa) medical management scenarios.

(UroToday.com) At this year’s virtual annual meeting, the Society of Urologic Oncology (SUO), in conjunction with the Young Urologic Oncologists (YUO), convened a Symposium on Clinical Research and Clinical Trials. In this context, Dr. Ian Murchie Thompson Jr. presented a talk focusing on the role of urologists in clinical trials, particularly as it relates to cooperative […]

(UroToday.com) In conjunction with this year’s virtual annual meeting, the Society of Urologic Oncology, in conjunction with the Young Urologic Oncologists (YUO), convened a Symposium on Clinical Research and Clinical Trials. In this context, Dr. Tracy Downs presented arguably one of the most important talks of the day, examining efforts to increase the enrollment of under-represented […]

(UroToday.com) The 2020 Young Urologic Oncologists paper of the year was awarded to Dr. Hiten Patel for his publication “Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial” published earlier this year in European Urology.1